Global Women’s Health Diagnostics Market Size study & Forecast, by Application (Cancer, Infectious Disease, Osteoporosis) and End Use (Hospitals, Laboratory, Home Care) and Regional Forecasts 2025-2035

The Global Women’s Health Diagnostics Market, currently valued at USD 20.6 billion in 2024, is set to witness remarkable expansion at a CAGR of 7.30% during the forecast period from 2025 to 2035. As the healthcare sector increasingly shifts toward precision medicine and early disease detection, the role of specialized diagnostics in women’s health has gained unprecedented significance. These diagnostics are critical for identifying and monitoring conditions such as breast and cervical cancer, reproductive health disorders, osteoporosis, and infectious diseases that disproportionately impact women. The rising prevalence of these conditions, coupled with heightened awareness campaigns and enhanced screening programs, is prompting healthcare systems to strengthen diagnostic infrastructure. Technological advances, particularly in molecular testing, imaging modalities, and AI-driven diagnostic platforms, are enabling clinicians to diagnose diseases earlier and with greater accuracy—thereby improving treatment outcomes and reducing long-term healthcare costs.

The momentum in market growth is further bolstered by increasing government-backed screening initiatives, rising investments from private healthcare providers, and the expansion of insurance coverage for preventive testing. Global data on women’s health highlights an alarming upward trend in cases of breast and cervical cancer, particularly in low- and middle-income regions, underscoring the urgent need for accessible and affordable diagnostic solutions. Furthermore, the expanding reach of point-of-care testing—particularly for pregnancy, fertility, and sexually transmitted infections—has created a more decentralized and patient-friendly diagnostic environment. While these advancements open vast opportunities, market expansion may be challenged by high diagnostic equipment costs, limited laboratory infrastructure in rural areas, and disparities in access to advanced healthcare services. Nevertheless, increasing R&D investment and the integration of digital health solutions present lucrative growth prospects for industry players in the coming decade.

Regionally, North America currently holds the largest market share, underpinned by robust healthcare infrastructure, advanced diagnostic technologies, and a high rate of adoption for early screening programs. The region benefits from strong public and private funding for women’s health research and innovation, along with an established network of specialized diagnostic centers. Europe follows closely, driven by government mandates for population-wide cancer screening and extensive awareness initiatives spearheaded by healthcare organizations. The Asia Pacific region, however, is anticipated to record the fastest growth through 2035, owing to rising healthcare expenditure, a growing emphasis on preventive care, and the integration of advanced diagnostic solutions in emerging economies like China and India. Additionally, improvements in healthcare access, rapid urbanization, and favorable policy frameworks are accelerating adoption rates in the region. Latin America and the Middle East & Africa are also making strides, supported by international collaborations, increasing private investment, and expanding diagnostic service networks targeting underserved populations.

Major market player included in this report are:
• Abbott Laboratories
• Hologic, Inc.
• Siemens Healthineers AG
• F. Hoffmann-La Roche Ltd.
• Quest Diagnostics Incorporated
• Thermo Fisher Scientific Inc.
• BD (Becton, Dickinson and Company)
• Cardinal Health, Inc.
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• GE HealthCare Technologies Inc.
• PerkinElmer Inc.
• Fujifilm Holdings Corporation
• Agilent Technologies, Inc.
• GenMark Diagnostics, Inc.

Global Women’s Health Diagnostics Market Report Scope:
• Historical Data – 2023, 2024
• Base Year for Estimation – 2024
• Forecast period - 2025-2035
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players.

The detailed segments and sub-segments of the market are explained below:

By Application:
• Cancer
• Infectious Disease
• Osteoporosis

By End Use:
• Hospitals
• Laboratory
• Home Care

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

Latin America
• Brazil
• Mexico

Middle East & Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2025 to 2035.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions. Show more